Glenmark Pharmaceuticals, an India-based drug manufacturer has issued a voluntary recall affecting nearly 1.48 million bottles of atomoxetine, a generic medication used to treat ADHD.

Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit ...

Glenmark Pharmaceuticals is recalling around 14.76 lakh bottles of Atomoxetine Capsules due to detected CGMP deviations and ...

As national pressure mounts for some medications for the mind, the FDA is highlighting a question that arose for a major ...

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to ...

ADHD is a neurodevelopmental disorder that affects a person's ability to focus, control impulses, and regulate their activity ...

The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark ...

Discover the commercial and brand names of the generic drug Atomoxetine. This indispensable guide is essential for healthcare professionals, patients, caregivers, and anyone seeking to understand ...

Clinical trial data indicate that atomoxetine is safe and well tolerated for the treatment of ADHD; however, safety data about long-term use (greater than one year) are unavailable. Adverse events ...

Glenmark Pharmaceuticals is recalling 15 lakh bottles of Atomoxetine Capsules in the US due to an N-Nitroso Atomoxetine ...

Glenmark Pharmaceuticals Inc, USA, an arm of the Mumbai-based Glenmark Pharmaceuticals, is recalling around 14.76 lakh ...